JP7094941B2 - Ｆｃｒｎ抗体及びその使用方法 - Google Patents

Ｆｃｒｎ抗体及びその使用方法 Download PDF

Info

Publication number
JP7094941B2
JP7094941B2 JP2019504902A JP2019504902A JP7094941B2 JP 7094941 B2 JP7094941 B2 JP 7094941B2 JP 2019504902 A JP2019504902 A JP 2019504902A JP 2019504902 A JP2019504902 A JP 2019504902A JP 7094941 B2 JP7094941 B2 JP 7094941B2
Authority
JP
Japan
Prior art keywords
sequence
cdr
antibody
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019504902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526540A (ja
JP2019526540A5 (cg-RX-API-DMAC10.html
Inventor
レオナ イー． リング
スチャリタ ロイ
ナサニエル ワッシュバーン
マリリン ケーリー
デビット ジェイ． キング
ジェイムズ ザ サード ミーダー
アンソニー マニング
ジャン ヒルソン
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2019526540A publication Critical patent/JP2019526540A/ja
Publication of JP2019526540A5 publication Critical patent/JP2019526540A5/ja
Priority to JP2022100315A priority Critical patent/JP7442575B2/ja
Application granted granted Critical
Publication of JP7094941B2 publication Critical patent/JP7094941B2/ja
Priority to JP2024023875A priority patent/JP2024059765A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
JP2019504902A 2016-07-29 2017-07-31 Ｆｃｒｎ抗体及びその使用方法 Active JP7094941B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022100315A JP7442575B2 (ja) 2016-07-29 2022-06-22 Ｆｃｒｎ抗体及びその使用方法
JP2024023875A JP2024059765A (ja) 2016-07-29 2024-02-20 Ｆｃｒｎ抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368803P 2016-07-29 2016-07-29
US201662368770P 2016-07-29 2016-07-29
US62/368,770 2016-07-29
US62/368,803 2016-07-29
PCT/US2017/044765 WO2018023136A1 (en) 2016-07-29 2017-07-31 Fcrn antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100315A Division JP7442575B2 (ja) 2016-07-29 2022-06-22 Ｆｃｒｎ抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019526540A JP2019526540A (ja) 2019-09-19
JP2019526540A5 JP2019526540A5 (cg-RX-API-DMAC10.html) 2020-09-03
JP7094941B2 true JP7094941B2 (ja) 2022-07-04

Family

ID=61016731

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504902A Active JP7094941B2 (ja) 2016-07-29 2017-07-31 Ｆｃｒｎ抗体及びその使用方法
JP2022100315A Active JP7442575B2 (ja) 2016-07-29 2022-06-22 Ｆｃｒｎ抗体及びその使用方法
JP2024023875A Pending JP2024059765A (ja) 2016-07-29 2024-02-20 Ｆｃｒｎ抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022100315A Active JP7442575B2 (ja) 2016-07-29 2022-06-22 Ｆｃｒｎ抗体及びその使用方法
JP2024023875A Pending JP2024059765A (ja) 2016-07-29 2024-02-20 Ｆｃｒｎ抗体及びその使用方法

Country Status (22)

Country Link
US (2) US11345751B2 (cg-RX-API-DMAC10.html)
EP (2) EP3491025B1 (cg-RX-API-DMAC10.html)
JP (3) JP7094941B2 (cg-RX-API-DMAC10.html)
KR (3) KR102717601B1 (cg-RX-API-DMAC10.html)
CN (2) CN109790221B (cg-RX-API-DMAC10.html)
AU (1) AU2017301915B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019001806A2 (cg-RX-API-DMAC10.html)
CA (1) CA3032415A1 (cg-RX-API-DMAC10.html)
DK (1) DK3491025T3 (cg-RX-API-DMAC10.html)
ES (1) ES2968439T3 (cg-RX-API-DMAC10.html)
FI (1) FI3491025T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240048T1 (cg-RX-API-DMAC10.html)
HU (1) HUE065780T2 (cg-RX-API-DMAC10.html)
IL (3) IL264528B2 (cg-RX-API-DMAC10.html)
LT (1) LT3491025T (cg-RX-API-DMAC10.html)
PL (1) PL3491025T3 (cg-RX-API-DMAC10.html)
PT (1) PT3491025T (cg-RX-API-DMAC10.html)
RS (1) RS65070B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201900813RA (cg-RX-API-DMAC10.html)
SI (1) SI3491025T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400004T1 (cg-RX-API-DMAC10.html)
WO (1) WO2018023136A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506786A (ja) * 2017-12-13 2021-02-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP2021061854A (ja) * 2015-01-30 2021-04-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP2022126783A (ja) * 2016-07-29 2022-08-30 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
US12528867B2 (en) 2018-07-20 2026-01-20 Momenta Pharmaceuticals, Inc. FCRN antibody compositions

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019023687A2 (pt) 2017-05-11 2020-06-02 National University Of Singapore Prevenção direcionada de transmissão de infecção vertical de mãe para feto
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
US12054558B2 (en) 2018-05-23 2024-08-06 The Jackson Laboratory Anti-NGly-1 antibodies and methods of use
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
IL280280B2 (en) * 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
EP3969125A4 (en) * 2019-05-17 2023-01-11 Alexion Pharmaceuticals, Inc. USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
EP4061486A1 (en) * 2019-11-19 2022-09-28 Immunovant Sciences GmbH Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
CN116234827B (zh) * 2021-09-03 2026-07-14 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
WO2024147074A1 (en) * 2023-01-06 2024-07-11 argenx BV Methods for treating pots using fcrn antagonists
USD1123829S1 (en) * 2023-10-10 2026-04-28 Shenzhen WETON Technology Co., Ltd. Rechargeable card holder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523351A (ja) 2008-04-25 2011-08-11 ダイアックス、コープ ＦｃＲｎに対する抗体及びその使用
JP2014523737A (ja) 2011-06-02 2014-09-18 ダイアックス コーポレーション Ｆｃレセプター結合タンパク質
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1345751A (en) 1918-09-23 1920-07-06 Dewrance John Multiple-way stop-valve
AU3928593A (en) 1992-04-01 1993-11-08 Merck & Co., Inc. Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
CN101421297A (zh) 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2666478A3 (en) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Uses and compositions for treatment of psoriasis
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
CN103026413B (zh) 2011-02-15 2016-04-20 松下电器产业株式会社 转台
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
US9959576B2 (en) 2011-12-07 2018-05-01 Visa International Service Association Multi-purpose device having multiple certificates including member certificate
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
JP5986637B2 (ja) 2012-09-26 2016-09-06 テルモ株式会社 薬液投与装置
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2991666B1 (en) 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
EP4241852A3 (en) * 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
PL3590962T3 (pl) 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
JP2018527903A (ja) 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
KR20190015704A (ko) 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
WO2018142618A1 (ja) 2017-02-06 2018-08-09 三菱電機株式会社 スケジューラ装置およびスケジューリング方法
JP6913527B2 (ja) 2017-06-22 2021-08-04 株式会社小松製作所 油圧ポンプおよびモータ
MX2020003619A (es) 2017-10-04 2020-10-28 Alexion Pharma Inc Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
WO2019194277A1 (ja) 2018-04-05 2019-10-10 株式会社Ｓｏｋｅｎ 飛行装置および飛行装置誘導システム
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
IL280280B2 (en) 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
CN113423426B (zh) 2018-11-06 2025-02-18 依牧诺万科学有限公司 使用抗FcRn抗体治疗格雷夫斯眼病的方法
CA3148826A1 (en) 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
CA3200972A1 (en) 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
MX2023012032A (es) 2021-04-12 2023-12-08 Momenta Pharmaceuticals Inc Composiciones y métodos para tratar la miastenia gravis pediátrica.
WO2022240875A1 (en) 2021-05-13 2022-11-17 Scipher Medicine Corporation Assessing responsiveness to therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523351A (ja) 2008-04-25 2011-08-11 ダイアックス、コープ ＦｃＲｎに対する抗体及びその使用
JP2014523737A (ja) 2011-06-02 2014-09-18 ダイアックス コーポレーション Ｆｃレセプター結合タンパク質
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood，2015年，126(23)，3472，http://doi.org/10.1182/blood.V126.23.3472.3472

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021061854A (ja) * 2015-01-30 2021-04-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP7442575B2 (ja) 2016-07-29 2024-03-04 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
JP2022126783A (ja) * 2016-07-29 2022-08-30 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
US12655209B2 (en) 2016-07-29 2026-06-16 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
JP2024059765A (ja) * 2016-07-29 2024-05-01 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
US11773168B2 (en) 2017-12-13 2023-10-03 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
JP2024016042A (ja) * 2017-12-13 2024-02-06 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP7420720B2 (ja) 2017-12-13 2024-01-23 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP7690538B2 (ja) 2017-12-13 2025-06-10 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP2025143252A (ja) * 2017-12-13 2025-10-01 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP2021506786A (ja) * 2017-12-13 2021-02-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP7904366B2 (ja) 2017-12-13 2026-08-12 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
US12528867B2 (en) 2018-07-20 2026-01-20 Momenta Pharmaceuticals, Inc. FCRN antibody compositions

Also Published As

Publication number Publication date
WO2018023136A1 (en) 2018-02-01
CN109790221B (zh) 2023-12-26
EP3491025A4 (en) 2020-05-27
CA3032415A1 (en) 2018-02-01
CN109790221A (zh) 2019-05-21
IL302288B2 (en) 2025-09-01
US12655209B2 (en) 2026-06-16
JP2022126783A (ja) 2022-08-30
JP2024059765A (ja) 2024-05-01
FI3491025T3 (fi) 2024-01-12
SMT202400004T1 (it) 2024-03-13
HUE065780T2 (hu) 2024-06-28
BR112019001806A2 (pt) 2019-05-07
IL302288B1 (en) 2025-05-01
NZ789871A (en) 2026-01-30
PL3491025T3 (pl) 2024-03-25
KR20190037285A (ko) 2019-04-05
IL264528B2 (en) 2023-09-01
EP3491025A1 (en) 2019-06-05
IL264528A (cg-RX-API-DMAC10.html) 2019-03-31
SG11201900813RA (en) 2019-02-27
JP7442575B2 (ja) 2024-03-04
KR102717601B1 (ko) 2024-10-16
JP2019526540A (ja) 2019-09-19
CN117679506A (zh) 2024-03-12
NZ750462A (en) 2024-04-26
AU2017301915B2 (en) 2024-09-12
AU2017301915A1 (en) 2019-02-28
DK3491025T3 (da) 2024-01-15
US20210238275A1 (en) 2021-08-05
LT3491025T (lt) 2023-11-27
EP4282487A2 (en) 2023-11-29
KR102505995B1 (ko) 2023-03-08
RS65070B1 (sr) 2024-02-29
HRP20240048T1 (hr) 2024-03-29
SI3491025T1 (sl) 2024-02-29
US20230049725A1 (en) 2023-02-16
IL264528B1 (en) 2023-05-01
IL320058A (en) 2025-06-01
US11345751B2 (en) 2022-05-31
ES2968439T3 (es) 2024-05-09
KR20240151878A (ko) 2024-10-18
EP4282487A3 (en) 2024-02-14
PT3491025T (pt) 2024-01-18
EP3491025B1 (en) 2023-10-18
KR20230035439A (ko) 2023-03-13
IL302288A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7442575B2 (ja) Ｆｃｒｎ抗体及びその使用方法
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
KR102904658B1 (ko) FcRn 항체 및 이의 사용 방법
HK40104376A (en) Fcrn antibodies and methods of use thereof
BR122024008593A2 (pt) Anticorpo isolado que se liga ao fcrn humano, seus usos e seu método de preparação, bem como molécula de ácido nucleico, vetor, célula hospedeira e composição farmacêutica
HK40002836A (en) Fcrn antibodies and methods of use thereof
HK40002836B (en) Fcrn antibodies and methods of use thereof
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200720

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210712

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210729

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220622

R150 Certificate of patent or registration of utility model

Ref document number: 7094941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250